Talphera, Inc. — 2023 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2023; it does not provide standalone fourth-quarter results. Talphera is a development-stage specialty pharmaceutical company. Its main focus is Niyad, a nafamostat-based regional anticoagulant candidate for dialysis circuits. Other programs include IV nafamostat candidate LTX-608 and licensed ephedrine and phenylephrine pre-filled syringe candidates.
In April 2023, Talphera divested DSUVIA/DZUVEO to Alora and classified that business as discontinued operations. Talphera retained certain payment rights and continued its role supporting DSUVIA sales to the U.S. Department of Defense. The company changed its name from AcelRx Pharmaceuticals to Talphera in January 2024.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from continuing operations | $0.651 million | None |
| Research and development expense | $5.546 million | $3.341 million |
| Selling, general and administrative expense | $11.994 million | $17.011 million |
| Operating loss | $16.889 million | $25.300 million |
| Net loss from continuing operations | $10.287 million | Net income of $59.125 million |
| Net loss from discontinued operations | $8.110 million | $11.370 million |
| Consolidated net income (loss) | $(18.397) million | $47.755 million |
| Net cash used in operating activities | $17.492 million | $28.331 million |
At year-end, cash and cash equivalents were $5.721 million and short-term investments were $3.660 million, totaling $9.381 million. Total assets were $20.395 million, total liabilities $6.290 million, and stockholders’ equity $14.105 million. The company had no long-term debt at year-end: it repaid approximately $3.4 million due to Oxford in April 2023 and terminated the loan agreement. No meaningful operating margin or gross margin is presented for this development-stage business.
Revenue and operating expenses above are continuing operations; cash-flow figures include discontinued operations. Operating cash use improved year over year, but liquidity fell from $20.770 million in cash, restricted cash and short-term investments at December 31, 2022. The 2022 net income was largely driven by an $84.052 million non-cash gain from terminating the Zalviso royalty monetization, so the year-over-year earnings comparison is not indicative of a comparable operating trend.
Material changes and unusual items
- R&D expense rose 66%, principally due to higher Niyad spending. SG&A fell 29%, mainly due to lower headcount and reduced consulting and legal costs.
- Continuing-operations revenue in 2023 was primarily the company’s $0.651 million in fees from supporting DSUVIA sales to the DoD. Separately, discontinued operations recorded $0.501 million of revenue and an $8.110 million net loss, including a $6.853 million loss on sale and impairment charges.
- 2023 other income included a $5.320 million gain from a decrease in the fair value of warrant liabilities. In 2022, results included the $84.052 million royalty-liability extinguishment gain and a $4.948 million impairment charge on Zalviso-related assets.
- Common shares outstanding increased to 16.953 million at year-end from 8.244 million a year earlier. In addition, 21.682 million warrants were outstanding at December 31, 2023, with a weighted-average exercise price of $1.40, representing potential dilution.
Outlook, risks and contingencies
- Management planned to begin enrollment in the 166-patient Niyad NEPHRO registrational trial in the first quarter of 2024, expected top-line data in the third quarter of 2024, and targeted a PMA submission by year-end 2024. These are plans, not assured outcomes; FDA approval is not assured.
- The filing states that existing resources, including subsequent financing, are not expected to fund planned operations through the next 12 months from the filing date without additional capital. Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern. Failure to secure funding could force program delays, reductions or discontinuation.
- After year-end, Talphera received $8.0 million from XOMA for specified future DSUVIA-related payments until a threshold is met; afterward, Talphera retains 50% of certain DoD royalties, sales milestones and related payments. The filing does not establish when, or whether, the threshold will be reached.
- A January 2024 private placement provided approximately $6.0 million upfront. Additional proceeds of approximately $10.0 million are contingent on a pivotal-trial milestone and approximately $2.0 million on a share-price milestone. These financings use pre-funded warrants and may significantly dilute existing stockholders.
- Key operating risks include clinical and regulatory uncertainty, dependence on single-source nafamostat suppliers and third-party manufacturers, limited reimbursement prospects, competition, and the need for further financing. Talphera is also exposed to risks from Alora’s ability to commercialize DSUVIA.
- Pending securities class-action and shareholder derivative matters remain unresolved. The company says it intends to defend them; it cannot estimate a reasonably possible loss or range of loss.
- Management reported effective disclosure controls and internal control over financial reporting at December 31, 2023. A prior material weakness related to earnings-per-share calculations had resulted in restatements of 2022 quarterly filings; management stated it had been remediated.
Important facts for investors to verify
- Current cash runway and the amount and timing of additional financing needed to sustain operations.
- Actual Niyad trial enrollment, results, regulatory interactions, and whether the 2024 data and PMA timetable remain achievable.
- Terms and dilution implications of outstanding warrants and the conditional January 2024 financing tranches.
- Alora’s DSUVIA sales performance, XOMA threshold progress, and potential value and timing of retained payments.
- Updates on the securities and derivative litigation, and continued effectiveness of financial reporting controls.